Infiltrating the immunological synapse: prospects for the use of altered peptide ligands for the treatment of immune pathology

  • Paul J. Fairchild
Part of the Progress in Inflammation Research book series (PIR)


For many years, T cell activation was thought to lack finesse, engagement of the T cell receptor (TCR) resulting in the full spectrum of responses and changes in gene expression associated with activation. The inflexibility of such an all-or-nothing response provided few strategies for intervention in ongoing immune pathology, the most effective approach being the prevention of TCR engagement by MHC blockade. The use of surrogate peptides to compete for binding with the pathogenic epitope relied solely on their high affinity for the relevant MHC restriction element rather than any similarity in sequence to the pathogenic epitope [1]. The first description of altered peptide ligands (APL) therefore served as a turning point in understanding of T cells and their mode of antigen recognition, and suggested alternative approaches to immune intervention that relied on use of ligands that differ almost imperceptibly from the wild-type epitope, guaranteeing their recognition by the relevant T cells.


Immunological Synapse Altered Peptide Ligand Experimental Autoimmune Encephalo Cell Receptor Ligand Cell Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fairchild PJ, Wraith DC (1992) Peptide-MHC interactions in autoimmunity. Curr Opin Immunol 4: 748–753PubMedCrossRefGoogle Scholar
  2. 2.
    De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FCA, Grey HM, Sette A (1992) Antigen-analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68: 625–634PubMedCrossRefGoogle Scholar
  3. 3.
    Jameson SC, Carbone FR, Bevan MJ (1993) Clone-specific T cell receptor antagonists of MHC class I-restricted cytotoxic T lymphocytes. J Exp Med 177: 1541–1550PubMedCrossRefGoogle Scholar
  4. 4.
    Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta FCA, Colon SM et al (1993) Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol 150: 1–7PubMedGoogle Scholar
  5. 5.
    Sloan-Lancaster J, Allen PM (1996) Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 14: 1–27PubMedCrossRefGoogle Scholar
  6. 6.
    Evavold BD, Sloan-Lancaster J, Allen PM (1993) Tickling the T cell receptor: selective T cell functions stimulated by altered peptide ligands. Immunol Today 14: 602–609PubMedCrossRefGoogle Scholar
  7. 7.
    Evavold BD, Allen PM (1991) Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308–1310PubMedCrossRefGoogle Scholar
  8. 8.
    Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM (1993) Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol 150: 3131–3140PubMedGoogle Scholar
  9. 9.
    Reis e Sousa C, Levine EH, Germain RN (1996) Partial signalling by CD8+ T cells in response to antagonist ligands. J Exp Med 184: 149–157PubMedCrossRefGoogle Scholar
  10. 10.
    Sloan-Lancaster J, Evavold BD, Allen PM (1993) Induction of T cell anergy by altered T cell receptor ligand on live antigen presenting cells. Nature 363: 156–159PubMedCrossRefGoogle Scholar
  11. 11.
    Sloan-Lancaster J, Evavold BD, Allen PM (1994) Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 180: 1195–1205PubMedCrossRefGoogle Scholar
  12. 12.
    Tao X, Grant C, Constant S, Bottomly K (1997) Induction of IL-4 producing CD4+ T cells by antigenic peptides altered for T cell receptor binding. J Immunol 158: 4237–4244PubMedGoogle Scholar
  13. 13.
    Fairchild PJ (1997) Altered peptide ligands: prospects for immune intervention in autoimmune disease. Eur J Immunogenet 24: 155–167PubMedCrossRefGoogle Scholar
  14. 14.
    Lyons DS, Lieberman SA, Hampl J, Boniface JJ, Chien Y, Berg LJ, Davis MM (1996) A T cell receptor binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5: 53–61PubMedCrossRefGoogle Scholar
  15. 15.
    Sykulev Y, Vugmeyster Y, Brunmark A, Ploegh HL, Eisen HN (1998) Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 9: 475–483PubMedCrossRefGoogle Scholar
  16. 16.
    La Face DM, Couture C, Anderson K, Shih G, Alexander J, Sette A, Mustelin T, Altman A, Grey HM (1997) Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J Immunol 158: 2057–2064PubMedGoogle Scholar
  17. 17.
    Smyth LA, Ardouin L, Williams O, Norton T, Tybulewicz V, Kioussis D (2002) Inefficient clustering of tyrosine-phosphorylated proteins at the immunological synapse in response to an antagonist peptide. Eur J Immunol 32: 3386–3394PubMedGoogle Scholar
  18. 18.
    Ehrlich LIR, Ebert PJR, Krummel MF, Weiss A, Davis MM (2002) Dynamics of p56lck translocation of the T cell immunological synapse following agonist and antagonist stimulation. Immunity 17: 809–822PubMedCrossRefGoogle Scholar
  19. 19.
    Huang J, Tilly D, Altman A, Sugie K, Grey HM (2000) T cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc Natl Acad Sci USA 97: 10923–10929PubMedCrossRefGoogle Scholar
  20. 20.
    Ding Y-H, Baker BM, Garboczi DN, Biddison WE, Wiley DC (1999) Four A6-TCR/ peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11: 45–56PubMedCrossRefGoogle Scholar
  21. 21.
    Robertson JM, Evavold BD (1999) Dueling T cell receptors: peptide antagonism of CD4+ T cells with dual antigen specificities. J Immunol 163: 1750–1754PubMedGoogle Scholar
  22. 22.
    Daniels MA, Schober SL, Hogquist KA, Jameson S C (1999) A test of the dominant negative signal model for T cell receptor antagonism. J Immunol 162: 3761–3764PubMedGoogle Scholar
  23. 23.
    Yang W, Grey HM (2003) Study of the mechanism of T cell receptor antagonism using dual T cell receptor-expressing T cells. J Immunol 170: 4532–4538PubMedGoogle Scholar
  24. 24.
    Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM (1994) Partial T cell signaling: altered phosphor-ζ and lack of ZAP-70 recruitment in APL-induced T cell anergy. Cell 79: 913–922PubMedCrossRefGoogle Scholar
  25. 25.
    Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN (1995) ζ phosphorylation without ZAP-70 activation induced by T cell receptor antagonists or partial agonists. Science 267: 515–518PubMedCrossRefGoogle Scholar
  26. 26.
    Singh RAK, Zhang JZ (2004) Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol 173: 7299–7307PubMedGoogle Scholar
  27. 27.
    Franco A, Southwood S, Arrhenius T, Kuchroo VK, Grey HM, Sette A, Ishioka GY (1994) T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 24: 940–946PubMedCrossRefGoogle Scholar
  28. 28.
    Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L (1994) Reversal of EAE by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and TNFa production. J Exp Med 180: 2227–2237PubMedCrossRefGoogle Scholar
  29. 29.
    Ostrov D, Krieger J, Sidney J, Sette A, Concannon P (1993) T cell receptor antagonism mediated by interaction between TCR junctional residues and peptide antigen analogues. J Immunol 150: 4277–4283PubMedGoogle Scholar
  30. 30.
    Gebe JA, Masewicz SA, Kochik SA, Reijonen H, Nepom GT (2004) Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T cells by nonantagonizable T cells. Eur J Immunol 34: 3337–3345PubMedCrossRefGoogle Scholar
  31. 31.
    Windhagen A, Scholz C, Höllsberg P, Fukaura H, Sette A, Hafler DA (1995) Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2: 373–380PubMedCrossRefGoogle Scholar
  32. 32.
    Nicholson LB, Waldner H, Carrizosa AM, Sette A, Collins M, Kuchroo VK (1998) Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci USA 95: 264–269PubMedCrossRefGoogle Scholar
  33. 33.
    Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K (1995) Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 181: 1569–1574PubMedCrossRefGoogle Scholar
  34. 34.
    Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397–405PubMedCrossRefGoogle Scholar
  35. 35.
    Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA et al (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167–1175PubMedCrossRefGoogle Scholar
  36. 36.
    Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 6: 1176–1182PubMedCrossRefGoogle Scholar
  37. 37.
    Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A (2002) Resistance of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 104: 105–114PubMedCrossRefGoogle Scholar
  38. 38.
    Waldmann H, Chen T-C, Graca L, Adams E, Daley S, Cobbold S, Fairchild PJ (2006) Regulatory T cells in transplantation. Semin Immunol 18: 111–119PubMedCrossRefGoogle Scholar
  39. 39.
    Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann, H (1996) T cell suppression in transplantation tolerance through linked suppression. J Immunol 156: 3602–3607PubMedGoogle Scholar
  40. 40.
    Chen T-C, Cobbold SP, Fairchild PJ, Waldmann H (2004) Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen. J Immunol 172: 5900–5907PubMedGoogle Scholar
  41. 41.
    Ben-David H, Venkata Aruna B, Sela M, Mozes E (2007) A dual altered peptide ligand inhibit myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells. Scand J Immunol 65: 567–576PubMedCrossRefGoogle Scholar
  42. 42.
    Sela M, Mozes E (2004) Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci USA 101: 14586–14592PubMedCrossRefGoogle Scholar
  43. 43.
    Venkata Aruna B, Sela M, Mozes E (2005) Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells. Proc Natl Acad Sci USA 102: 10285–10290CrossRefGoogle Scholar
  44. 44.
    Ben-David H, Sela M, Mozes E (2005) Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis. Proc Natl Acad Sci USA 102: 2028–2033PubMedCrossRefGoogle Scholar
  45. 45.
    Dayan M, Sthoeger Z, Neiman A, Abarbanel J, Sela M, Mozes E (2004) Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis. Hum Immunol 65: 571–577PubMedCrossRefGoogle Scholar
  46. 46.
    Venkata Aruna B, Sela M, Mozes E (2006) Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+CD25+ regulatory cells. J Neuroimmunol 177: 63–75CrossRefGoogle Scholar
  47. 47.
    Nicholson LB, Murtaza A, Hafler BP, Sette A, Kuchroo VK (1997) A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc Natl Acad Sci USA 94: 9279–9284PubMedCrossRefGoogle Scholar
  48. 48.
    Roopenian D, Choi EY, Brown A (2002) The immunogenomics of minor histocompatibility antigens. Immunol Rev 190: 86–94PubMedCrossRefGoogle Scholar
  49. 49.
    den Haan J, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF et al (1998) The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science 279: 1054–1057CrossRefGoogle Scholar
  50. 50.
    Fairchild PJ, Chen T-C, Waldmann H (2004) Altered peptide ligands as therapeutic agents for the treatment of allograft rejection. Curr Top Pept Protein Res 6: 237–244Google Scholar
  51. 51.
    Daniel C, Grakoui A, Allen PM (1998) Inhibition of an in vitro CD4+ T cell alloresponse using altered peptide ligands. J Immunol 160: 3244–3250PubMedGoogle Scholar
  52. 52.
    Colovai AI, Liu Z, Harris PE, Cortesini R, Suciu-Foca N (1997) Allopeptide-specific T cell reactivity altered by peptide analogs. J Immunol 158: 48–54PubMedGoogle Scholar
  53. 53.
    Burrows SR, Khanna R, Moss DJ (1999) Direct alloreactivity by human CTL can be inhibited by altered peptide ligand antagonism. Blood 93: 1020–1024PubMedGoogle Scholar
  54. 54.
    García-Peydro M, Paradela A, Albar JP, López de Castro JA (2000) Antagonism of direct alloreactivity of an HLA-B27-specific CTL clone by altered peptide ligands of its natural epitope. J Immunol 165: 5680–5685PubMedGoogle Scholar
  55. 55.
    den Haan JMM, Mutis T, Blokland E, Ijzerman AP, Goulmy E (2002) General T cell receptor antagonist to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T cell responses. Blood 99: 985–992CrossRefGoogle Scholar
  56. 56.
    de Koster HS, Vermeulen CJ, Hiemstra HS, Amons R, Drijfhout JW, Koning F (1999) Definition of agonists and design of antagonists for alloreactive T cell clones using synthetic peptide libraries. Int Immunol 11: 585–591PubMedCrossRefGoogle Scholar
  57. 57.
    Zelenika D, Adams E, Mellor A, Simpson E, Chandler P, Stockinger B, Waldmann H, Cobbold SP (1996) Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol 161: 1868–1874Google Scholar
  58. 58.
    Chen T-C, Waldmann H, Fairchild PJ (2004) Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J Clin Invest 113: 1754–1762PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Paul J. Fairchild
    • 1
  1. 1.Sir William Dunn School of PathologyUniversity of OxfordOxfordUK

Personalised recommendations